|
Hi, and Happy Friday! At our Q1 AI Roundtable webinar, Beyond ChatGPT: The AI Toolkit Every Communicator Needs in 2026, we got into the nitty-gritty of integrating AI into comms workflows. The discussion spanned research, drafting, stakeholder intelligence, and content production. T2B Pro members can click here to watch the replay and browse a comprehensive list of the resources shared. Top 10 Takeaways
Remember, AI is most useful when it amplifies existing communications judgment, and like any tool, it is only as good as the person using it. Huge thanks to Nathaniel Reagan (AI Learning Labs) and Matt Snodgrass (Syneos Health Communications) of the T2B AI Roundtable for leading another great session -- I'm still getting notes about it a couple weeks later! And also thank you to everyone who joined the discussion and shared the tools and workflows they’re experimenting with. Lynnea |
Hi! While our field has its own regulatory, scientific, and stakeholder complexities, many of the judgment calls we face around trust, executive counsel, reputation, and change aren’t unique to biotech. Communicators in other highly scrutinized sectors often navigate similar pressures, often with lessons that translate in useful ways. Tomorrow’s Comm Convo brings together communications leaders who have worked both inside and outside of biopharma. They’ll share how working in other industries...
Hi, and Happy Friday! At our Q1 IR Roundtable event, How ESG Drives Trust Among Investors and Patients Alike, our guest speakers dug into ESG with a biopharma lens, exploring how we can approach ESG in a way that strengthens credibility. ESG is most effective when it helps stakeholders understand how a company manages risk and makes decisions, rather than being positioned as a separate corporate responsibility exercise. If you weren’t able to join us live, T2B Pro and Student members can...
Hi! At our very first Patient Advocacy & Engagement Roundtable discussion, Patient Stories Without a Fixed Address, the conversation with leaders from Astellas, Bayer, and Atrium Therapeutics focused on what patient centricity looks like when it is treated as a strategic business priority. A consistent theme emerged: Organizations that build strong patient relationships tend to do so by embedding patient perspectives early, operationalizing what they hear, and protecting the integrity of the...